B
Bull
Bull · 25%RCEL
$9.30
Precio del escenario
$10.070
-0.030 (-0.30%)Al cierre
Loading chart…
- High
- 10.290
- Open
- 10.020
- VWAP
- 10.11
- Vol
- 142.65K
- Mkt Cap
- 205.11M
- Low
- 9.970
- Amount
- 1.44M
- EV/EBITDA, TTM
- -7.53
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.
AI analysis of AVITA Medical Inc (RCEL)
buyAVITA Medical Inc (RCEL) is a good buy right now, trading at $10.35 with a strong recent performance of 198.27% year-to-date. The RSI is at 73.4, indicating strong momentum, and analysts have raised their price targets to a range of $11 to $14, suggesting significant upside potential. The main risk is the company's ongoing net losses, which were $7.66 million in Q2 2026, but the trend shows improvement in revenue and cost management.
Métricas de valoración
The current forward P/E ratio for AVITA Medical Inc (RCEL) is 10.29, compared to its 5-year average forward P/E of -0.84.
Alphio AI Price Scenarios for RCEL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
1.008-09GlobenewswireAVITA Medical Invites Investors to Webinar on Q2 Results
1.008-09NewsfilterAVITA Medical Invites Investors to Webinar on Q2 Results
- 1.008-07Newsfilter
AVITA Medical to Participate in Growth Conference
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
- 1.005-17Newsfilter
AVITA Medical Hosts Investor Webinar on May 20, 2026
RCEL FAQ — answered by Alphio AI
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
AVITA Medical Inc (RCEL) is a good buy right now, trading at $10.35 with a strong recent performance of 198.27% year-to-date. The RSI is at 73.4, indicating strong momentum, and analysts have raised their price targets to a range of $11 to $14, suggesting significant upside potential. The main risk is the company's ongoing net losses, which were $7.66 million in Q2 2026, but the trend shows improvement in revenue and cost management.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.